1)Burris HA, 3rd, et al:Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial. J Clin Oncol 15:2403-2413, 1997
2)Moore MJ, et al:Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
3)Conroy T, et al:FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825, 2011
4)National Comprehensive Cancer Network(NCCN)Clinical Practice in Oncology, Pancreatic Adenocarcinoma. Version 2, 2011
5)Okusaka T, et al:A late phase Ⅱ study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 61:615-621, 2008
6)Pelzer U, et al:A randomized trial in patients with gemcitabine-refractory pancreatic cancer. Final results of the CONKO 003 study.(abstract). J Clin Oncol 26:215s, 2008